TruTrace Technologies Inc (CSE:TTT) (OTCMKTS:TTTSF) announced Wednesday that its medical cannabis verification pilot program with Shoppers Drug Market has added another industry player: Tilray Inc (NASDAQ:TLRY).
Tilray Canada, a subsidiary, joins a slate of companies lined up to use TruTrace’s StrainSecure technology to track strains of medical cannabis and verify their authenticity.
The program is expected to help researchers and clinicians match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume.
The latest addition comes a few weeks after TruTrace announced the completion of Phase 1 of the program. Looking ahead, implementation of the program is expected by November.
TruTrace CEO Robert Galarza was pleased to have a company of Tilray’s calibre on board.
"Tilray has maintained a keen focus on the importance of quality medical cannabis, from their clinical research initiatives to their strategic partnerships in the global medical market," Galarza said in a statement. "We are very excited to begin working with them in the pilot program, and we believe our blockchain-enabled verification and traceability of their products will only further bolster their global brand."
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel